Endometriosis is a chronic, often debilitating condition affecting one in nine women and girls of reproductive age – yet diagnosis takes an average of seven years, requiring complex imaging (TVUS ± MRI) and sometimes surgery to confirm disease.
Proteomics International, the Royal Women’s Hospital and the University of Melbourne are working together to advance Promarker®Endo – a first-of-its-kind blood test designed to reduce and alleviate the long diagnostic pathway.
This collaboration leverages the world’s largest biobank of endometriosis samples, housed at the Royal Women's Hospital, combined with University research and clinical expertise, and Proteomics International’s proprietary biomarker platform technology.
The project aims to validate next-generation diagnostics capable of identifying endometriosis across all disease stages, including early-stage cases that are not detected through imaging and can be missed during surgery.
Key facts
- FACULTY: Faculty of Medicine, Dentistry and Health Sciences
- SECTOR: Women’s Health; Diagnostics
- PARTNERSHIP COMMENCED: 2021
- IMPACT PATHWAY: Partnership
- SUSTAINABLE DEVELOPMENT GOALS ADDRESSED: Good Health and Well-Being; Gender Equality
Banner image: Wikimedia Commons
Thumbnail image: Proteomics International
First published on 23 June 2026.
Share this article